规格: | 5mg | 产品价格: | 880 |
---|
规格: | 25mg | 产品价格: | 2220 |
---|
Catalog Number GC14224
Molecular Formula C52H79N5O12
Relative Molecular Mass 966.21
CAS Registry Number 221877-54-9
Formulation A solid
Purity ≥98%
Storage Desiccate at -20°C
产品描述
Zotarolimus(ABT-578) is an anti-proliferative drug used exclusively in coronary drug eluting stent [1]. Zotarolimus(ABT-578) is an analogue of rapamycin and an anti-proliferative drug. Zotarolimus exhibited high affinity to the immunophilin FKBP12 and inhibited T cells proliferation [1]. Zotarolimus inhibited FKBP-12 binding with IC50 value of 2.8 nM. In human coronary artery cells, zotarolimus inhibited smooth muscle cell (SMC) and endothelial cell (EC) proliferation with IC50 values of 2.9 and 2.6 nM, respectively [2]. In human blood-derived peripheral blood mononuclear cells (PBMC) and rat splenocytes, zotarolimus inhibited Con A-induced human and rat T cell proliferation with IC50 values of 7.0 and 1337 nM respectively in a concentration-dependent way. In lymphocytes derived from humans or rats, zotarolimus inhibited the human and rat mixed lymphocyte reaction (MLR) with IC50 values of 1.2 and 1465 nM respectively in a concentration-dependent way. Also, zotarolimus inhibited human coronary artery smooth muscle cell proliferation induced by growth factor with IC50 value of 0.8 nM [3]. In crossbred juvenile swine, zotarolimus-eluting PC-coated stents induced a lower percent lumen stenosis, less neointimal area, less neointimal thickness and greater lumen area [2]. In a rat adjuvant DTH model mediated by T cell, zotarolimus inhibited the rat adjuvant DTH response with value of 1.72 mg/kg/day [3]. References:[1]. Brugaletta S, Burzotta F, Sabaté M. Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective. Expert Opin Pharmacother, 2009, 10(6): 1047-1058.[2]. Garcia-Touchard A, Burke SE, Toner JL, et al. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J, 2006, 27(8): 988-993.[3]. Chen YW, Smith ML, Sheets M, et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol, 2007, 49(4): 228-235.
更多产品信息,请点击:https://www.glpbio.cn/search.php?catalog=GC14224原装进口,Zotarolimus(ABT-578),美国GlpBio品Pai大包装更优惠!
美国Glpbio是一家领先的小分子YZ剂、激活剂、化合物库、多肽和实验室试剂的供应商。公司经营范围广泛,产品涉及癌症、免疫学、神经科学、细胞凋亡、表观遗传学等20多个不同研究领域,拥有10000多种产品。总部位于美国加利福尼亚,营销网点遍及法国、德国、加拿大、日本、澳大利亚、新加坡、以色列等20多个国家地区,竭诚为各国的科研工作者提供优质的产品和专业的服务。
![](http://item.yiqi.com/pic/ConPic/4/3323125216116756959-14.jpg)
![](http://item.yiqi.com/pic/ConPic/4/3323126197516789367-14.jpg)
温馨提示:不可用于临床ZL。